Bulk Pharma Group B
ID: 75A50325R00003Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEASPR/ORM-SNSAtlanta, GA, 30341, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
  1. 1
    Posted Jan 3, 2025, 12:00 AM UTC
  2. 2
    Updated Jan 3, 2025, 12:00 AM UTC
  3. 3
    Due Jan 17, 2025, 7:00 PM UTC
Description

The Department of Health and Human Services (HHS) is seeking proposals for the procurement of a range of FDA-approved pharmaceuticals as part of the Bulk Pharma Group B initiative. The contract will require the delivery of specific injectable medications, including Acyclovir Sodium, Doxycycline, Levophed, Meropenem, Sodium Chloride, and sterile water, with quantities detailed in the attached Request for Proposal (RFP). This procurement is critical for maintaining the Strategic National Stockpile, ensuring a reliable supply of essential pharmaceuticals for disaster preparedness and response efforts. Interested vendors must submit their proposals by the specified deadline, and inquiries can be directed to primary contact Terri Reed at terri.reed@hhs.gov or secondary contact Kimberly Golden at kimberly.golden1@hhs.gov.

Point(s) of Contact
Files
Title
Posted
Jan 3, 2025, 4:04 PM UTC
The document is a combined synopsis and solicitation for a federal government contract issued by the U.S. Department of Health and Human Services (HHS). The primary purpose is to procure pharmaceutical supplies for the Strategic National Stockpile, aimed at replenishing expired products. The solicitation number is 75A50325R00003, and it anticipates awarding a Firm Fixed Price type contract. There will be a base ordering period of 12 months, with four optional periods of the same duration. The acquisition is conducted under full and open competition and is not set aside for small businesses, with key details outlined including delivery locations and acceptance protocols. Supplementary sections detail the scope of supplies, evaluation criteria, and provisions necessary for contractor compliance, including specific terms related to performance evaluation, payment processing through electronic systems, and record-keeping obligations. Companies are required to submit proposals by the specified deadline, including a completed set of representations and certifications. Overall, this document lays the groundwork for the procurement process, emphasizing the necessity of pharmaceuticals in disaster preparedness and response efforts while adhering to existing federal regulations.
The document pertains to the federal RFP (Request for Proposal) 75A50325R00003, focusing on the procurement of specific pharmaceutical products for the Bulk Pharma Group B. It outlines the technical specifications for various injectable medications including Acyclovir Sodium, Doxycycline, Levophed, Meropenem, Sodium Chloride, and sterile water for injection, designated for delivery over multiple option years. Suppliers are required to specify their company name, business size, and provide detailed information about product packaging, including National Drug Code (NDC) and National Stock Number (NSN) where applicable. The file also requests past performance details from bidders, highlighting the necessity of demonstrating relevant experience in similar projects within the last three years. It emphasizes providing comprehensive project descriptions, including contract information, work narratives, financial details, and relevant contacts. Compliance with the Trade Agreement Act and Buy American Act is mandatory, along with proof of manufacturing or certified reseller status. This RFP is part of the federal initiative to ensure a reliable supply chain for essential pharmaceuticals, focusing on quality, compliance, and past performance evaluation to select qualified vendors effectively.
Jan 3, 2025, 4:04 PM UTC
The document pertains to RFP 75A50325R00003 for Bulk Pharma Group B, outlining a business template required for pharmaceutical product proposals. It requests detailed information from offerors regarding various pharmaceutical items, including Acyclovir, Doxycycline, Levophed, Meropenem, Sodium Chloride, and Sterile Water, specifying unit quantities and pricing for multiple option years. The template mandates the completion of fields such as total quantities provided by the U.S. Government (USG) for each option year, manufacturing details like NDC numbers, vendor's pricing for each product, and extended price calculations. The purpose of this RFP is to procure essential injectable medications from qualified suppliers, ensuring that bids can be compared across submissions for suitability and cost-effectiveness. This structured approach facilitates transparency and compliance with government procurement standards while providing a clear breakdown of expected quantities and pricing for evaluation by the awarding agency.
Jan 3, 2025, 4:04 PM UTC
The document is a question and answer sheet associated with the Request for Proposal (RFP) identified as Solicitation No. 75A50325R00003. It serves as a platform for contractors to submit inquiries about the RFP. Each entry provides sections for contractors' questions, detailing references to specific sections, paragraphs, and pages of the solicitation language. The government's responses are consolidated and provided directly below each question, indicating continuity in communication regarding the requirements and clarifications needed by potential vendors. The structure allows for systematic tracking of questions and responses, ensuring transparency and thorough understanding of the solicitation process. Overall, this Q&A sheet is a vital component of the RFP process, facilitating clear dialogue between the government and contractors to refine proposals and enhance compliance with outlined solicitations.
Jan 3, 2025, 4:04 PM UTC
The section 52.212-3 outlines the Offeror Representations and Certifications specific to commercial products and services, primarily emphasizing compliance with government contracting requirements. It requires Offerors to complete necessary certifications electronically through the System for Award Management (SAM). Key definitions are provided, including those for economically disadvantaged businesses, prohibited child labor scenarios, and ownership classifications such as small business and veteran-owned businesses. The document mandates disclosures related to federal tax liabilities, previous contract compliance, and restrictions on operations relating to Sudan and Iran. Additionally, certifications for products' compliance with the Buy American Act and trade agreement regulations are to be included. The provisions underscore various contextual business classifications, mirroring regulations observed in government RFPs and grants. The purpose of this document is to ensure that entities engaging in federal contracts adhere to specific ethical, legal, and operational standards, fostering transparency and accountability within government procurement processes.
The document appears to be related to federal and state procurement processes, specifically Request for Proposals (RFPs) and grants. It likely contains various details about initiatives aimed at soliciting contractor services or funding. Key topics may involve project objectives, eligibility criteria, application processes, deadlines, budget considerations, and reporting requirements. The structure of the document could include sections delineating the scope of work, evaluation criteria, and terms of agreement, thereby guiding organizations on how to respond effectively. Overall, the document emphasizes the importance of compliance with federal regulations and local laws in pursuit of funding opportunities. It underscores the federal government's commitment to transparent contracting, ensuring that selected proposals align with public policy goals and community needs. Stakeholders must carefully assess the outlined requirements and tailor their proposals to meet the specified objectives while adhering to all stipulated guidelines and deadlines.
Lifecycle
Title
Type
Bulk Pharma Group B
Currently viewing
Combined Synopsis/Solicitation
Similar Opportunities
6505--Metformin IR Tablets
Buyer not available
The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Metformin HCL IR Tablets as part of its pharmaceutical prime vendor programs, which also serve the Department of Defense (DoD). Offerors are required to submit pricing for various bottle sizes and quantities, ensure compliance with FDA regulations, and adhere to the Drug Supply Chain Security Act (DSCSA), including providing a unique National Drug Code (NDC) for each product. This procurement is crucial for maintaining a reliable source of pharmaceutical products, ensuring consistent availability and pricing while meeting federal regulatory standards. Interested parties should contact Senior Contract Specialist Teresa Hussain at teresa.hussain@va.gov for further details, and proposals must be submitted in accordance with the outlined requirements within the specified timeframe.
Valsartan/Hydrochlorothiazide Tablets
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Valsartan/Hydrochlorothiazide Tablets, which includes various dosages in 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are essential for treating hypertension and heart failure, and will serve customers including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in May 2025. Interested parties can reach out to Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for inquiries, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.
6505--Fludrocortisone Acetate Tablets (VA-25-00047932)
Buyer not available
The Department of Veterans Affairs is seeking offers for the procurement of Fludrocortisone Acetate Tablets (0.1 MG) under solicitation number 36E79725R0023, with an emphasis on compliance with federal regulations and pharmaceutical standards. Contractors are required to submit bids that include pricing for a base year and four option years, adhering to guidelines such as a 0.5% Cost Recovery Fee and compliance with the Drug Supply Chain Security Act. This procurement is crucial for ensuring a reliable supply of essential pharmaceuticals for veterans, reflecting the government's commitment to maintaining high standards in healthcare delivery. The deadline for submitting offers has been extended to April 21, 2025, at 2:30 PM Central Daylight Time, and interested parties should contact Contract Specialist Nicholas I McGregor at Nicholas.McGregor@va.gov for further information.
ADULT COVID-19 2025-2026
Buyer not available
The Centers for Disease Control and Prevention (CDC) is seeking proposals for one or more Indefinite Delivery Indefinite Quantity (IDIQ) contracts to purchase U.S.-licensed COVID-19 vaccines specifically for adults aged 19 and older. The objective of this procurement is to leverage Section 317 vaccine purchase funds to acquire vaccines at prices lower than those available in the commercial market, thereby supporting state and local health departments in immunizing populations at risk of under-vaccination. This initiative is crucial for enhancing adult immunization coverage and ensuring effective public health practices, as the awarded vaccines will be distributed to health departments and programs across the United States, including territories. Interested suppliers should contact Brian Swann at qty0@cdc.gov or James Sprigler at zbs6@cdc.gov for further details, with a maximum procurement potential of 10 million doses and specific ordering requirements outlined in the solicitation documents.
6505--Topiramate Tablets (VA-25-00047941)
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Topiramate Tablets, designated as Solicitation 36E79725R0031. This procurement aims to secure an uninterrupted supply of various forms of Topiramate for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), highlighting the importance of ensuring continuous access to essential pharmaceuticals across federal health services. The contract will span one year with four additional pre-priced option years, and interested vendors must submit their proposals electronically by April 29, 2025, while providing the exact name of the drug along with a unique National Drug Code (NDC). For further inquiries, vendors can contact Contract Specialist Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.
6505--Acyclovir Capsules (VA-25-00048078)
Buyer not available
The Department of Veterans Affairs is seeking proposals for the procurement of Acyclovir Capsules, specifically 200MG capsules in two packaging sizes, to support the healthcare needs of veterans. The solicitation includes two line items: Line Item 1 requires 3,256 bottles of 100 capsules per bottle, and Line Item 2 requests 15,475 bottles of 500 capsules per bottle, with the same quantities needed for the base year and each of the four option years. This procurement is crucial for ensuring a reliable supply of essential pharmaceuticals for veterans, emphasizing the importance of compliance and competition within the pharmaceutical supply chain. Interested suppliers must submit their pricing proposals by May 1, 2025, and can contact Contracting Officer Andrew Cazares at andrew.cazaeres@va.gov or (708) 786-4990 for further details.
Biorelevant characterization system for subcutaneous injections
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking vendors to provide a Biorelevant Characterization System for evaluating subcutaneous drug formulations. This system is intended to enhance the capabilities of the Center for Drug Evaluation and Research (CDER) by enabling the investigation of drug release performance under simulated physiological conditions, utilizing integrated sensors and automated operation for unattended assessments. The initiative underscores the FDA's commitment to ensuring the quality, safety, and efficacy of pharmaceutical products while promoting innovation and domestic manufacturing. Interested parties, particularly small businesses under NAICS Code 334516, are encouraged to submit their qualifications by contacting Erika Crawford at erika.crawford@fda.hhs.gov or Maria Finan at maria.finan@fda.hhs.gov, as this is a Sources Sought Notice for market research purposes only, with no contract to be awarded at this stage.
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Buyer not available
The Department of Defense (DoD) is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) and the Uniform Formulary Additional Discount Program (ADP) through the Defense Health Agency (DHA). This procurement aims to establish agreements for pharmaceutical agents that will be included in the DoD's Uniform Formulary, which is essential for providing effective pharmacy benefits to military personnel and their families. The upcoming Pharmacy and Therapeutics (P&T) Committee meeting, scheduled for May 7-8, 2025, will review newly approved drugs, with quotes due by April 17, 2025. Interested manufacturers should contact Keith Marasigan at keith.b.marasigan2.ctr@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil for further details and to ensure compliance with submission requirements.
Rabeprazole Sodium DR
Buyer not available
The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Rabeprazole Sodium DR 20MG Tablets. This procurement aims to fulfill the pharmaceutical needs of military personnel, emphasizing compliance with federal acquisition regulations and ethical conduct in contractor performance. Interested vendors must submit their proposals via the DLA's Internet Bid Board System (DIBBS) by May 15, 2025, and are encouraged to reach out to primary contact Trong Nguyen at Trong.Nguyen@dla.mil or secondary contact Jason Wray at jason.wray@dla.mil for further inquiries.
6505--Perphenazine Tablets (VA-25-00037353)
Buyer not available
The Department of Veterans Affairs (VA) is soliciting proposals for the procurement of Perphenazine tablets under solicitation number VA-25-00037353. This contract aims to supply specified quantities of the drug to both the VA and the Department of Defense (DoD) through their Pharmaceutical Prime Vendor (PPV) Programs, with a focus on service-disabled veteran-owned small businesses, women-owned small businesses, and HUBZone small businesses. The procurement is critical for ensuring a consistent supply of pharmaceutical products while adhering to regulatory requirements, including the Drug Supply Chain Security Act (DSCSA) and FDA Good Manufacturing Practices (cGMP). Interested offerors must contact Contract Specialist Anthony DiCrescenzo at Anthony.DiCrescenzo@va.gov for further details, and proposals must include a 0.5% Cost Recovery Fee and a unique National Drug Code (NDC) for each product.